{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T01:04:22Z","timestamp":1776474262174,"version":"3.51.2"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.amjcard.2023.07.108","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T11:07:15Z","timestamp":1691752035000},"page":"366-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Systematic Review and Meta-Analysis of Direct Oral Anticoagulants Versus Warfarin in Atrial Fibrillation With Low Stroke Risk"],"prefix":"10.1016","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-0800","authenticated-orcid":false,"given":"Khi Yung","family":"Fong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiong Huak","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0164-7925","authenticated-orcid":false,"given":"Vern Hsen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2023.07.108_bib0001","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0002","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0003","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0004","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-0041-1739411","article-title":"2021 Focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary","volume":"122","author":"Chao","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0006","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0007","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.119.041303","article-title":"Stroke risk as a function of atrial fibrillation duration and CHA2DS2-VASc score","volume":"140","author":"Kaplan","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0008","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2014.11.046","article-title":"Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?","volume":"65","author":"Chao","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0009","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3171\/2015.1.JNS141543","article-title":"Improved versus worsened endocrine function after transsphenoidal surgery for nonfunctional pituitary adenomas: rate, time course, and radiological analysis","volume":"124","author":"Jahangiri","year":"2016","journal-title":"J Neurosurg"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0011","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0012","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-155-10-201111150-00004","article-title":"Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial","volume":"155","author":"Oldgren","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0013","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(12)60986-6","article-title":"Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial","volume":"380","author":"Lopes","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0014","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1160\/TH15-06-0497","article-title":"Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation","volume":"114","author":"Seeger","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0015","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1161\/STROKEAHA.117.018773","article-title":"Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation","volume":"48","author":"Cha","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2017-000682","article-title":"Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation","volume":"4","author":"Friberg","year":"2017","journal-title":"Open Heart"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0017","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamacardio.2017.1883","article-title":"Effectiveness and safety of standard-dose nonvitamin K antagonist oral anticoagulants and warfarin among patients with atrial fibrillation with a single stroke risk factor: a nationwide cohort study","volume":"2","author":"Lip","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0018","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jacc.2018.05.066","article-title":"Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety","volume":"72","author":"Lee","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0019","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients","volume":"49","author":"Lip","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/ehjcvp\/pvy025","article-title":"Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1","volume":"5","author":"Coleman","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0021","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/ehjqcco\/qcab048","article-title":"Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study","volume":"8","author":"Halvorsen","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0022","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1093\/eurheartj\/ehac111","article-title":"Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study","volume":"43","author":"Komen","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0023","doi-asserted-by":"crossref","first-page":"27410","DOI":"10.1038\/srep27410","article-title":"Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study","volume":"6","author":"Nielsen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0024","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0025","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0026","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0027","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0028","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/clc.23257","article-title":"Risk of ischemic stroke and utility of CHA2 DS2 -VASc score in women and men with atrial fibrillation","volume":"42","author":"Tomasdottir","year":"2019","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0029","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1161\/STROKEAHA.115.012609","article-title":"Ischemic stroke risk in patients with atrial fibrillation and CHA2DS2-VASc score of 1","volume":"47","author":"Joundi","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0030","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0031","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/CIRCOUTCOMES.110.958108","article-title":"Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation","volume":"4","author":"Eckman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0032","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacc.2014.10.052","article-title":"Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1","volume":"65","author":"Friberg","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0033","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/bcp.14450","article-title":"Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation","volume":"87","author":"Souverein","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0034","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1093\/eurheartj\/ehac099","article-title":"Atrial fibrillation and stroke: who is low risk and what are we going to do about it?","volume":"43","author":"McIntyre","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0035","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/STROKEAHA.116.013253","article-title":"Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated?","volume":"47","author":"Fauchier","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0036","article-title":"Response by Fauchier et al. to letter regarding article \u201cshould atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated?\u201d","volume":"47","author":"Fauchier","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0037","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0038","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1161\/CIRCULATIONAHA.117.029081","article-title":"Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc?","volume":"137","author":"Nielsen","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0039","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/STROKEAHA.116.013880","article-title":"Validation of a modified CHA2DS2-VASc score for stroke risk stratification in Asian patients with atrial fibrillation: a nationwide cohort study","volume":"47","author":"Chao","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/14779072.2017.1281742","article-title":"Ischemic stroke risk in East Asian patients with CHA2DS2-VASc score of 1: systematic review and meta-analysis","volume":"15","author":"Bai","year":"2017","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0041","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1161\/STROKEAHA.117.018551","article-title":"CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke: a Korean nationwide cohort study","volume":"48","author":"Kim","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0042","doi-asserted-by":"crossref","first-page":"e13457","DOI":"10.1111\/eci.13457","article-title":"Factors influencing oral anticoagulant use in patients newly diagnosed with atrial fibrillation","volume":"51","author":"Bezabhe","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0043","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000504877","article-title":"Risk of stroke, bleeding, and death in patients with nonvalvular atrial fibrillation and chronic kidney disease","volume":"145","author":"Arnson","year":"2020","journal-title":"Cardiology"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0044","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1161\/CIRCULATIONAHA.115.016713","article-title":"Should patients with atrial fibrillation and 1 stroke risk factor (CHA2DS2-VASc score 1 in men, 2 in women) be anticoagulated? Yes: even 1 stroke risk factor confers a real risk of stroke","volume":"133","author":"Lip","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0045","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jamainternmed.2016.5954","article-title":"Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation","volume":"176","author":"Graham","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0046","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1160\/TH11-11-0784","article-title":"Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a \u2018real world\u2019 atrial fibrillation population: a modelling analysis based on a nationwide cohort study","volume":"107","author":"Banerjee","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0047","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1055\/s-0040-1714918","article-title":"Bleeding risk in nonvalvular atrial fibrillation patients receiving direct oral anticoagulants and warfarin: a systematic review and meta-analysis of observational studies","volume":"4","author":"Wang","year":"2020","journal-title":"TH Open"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0048","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1161\/STROKEAHA.118.022128","article-title":"Intravenous tPA (tissue-type plasminogen activator) in patients with acute ischemic stroke taking non\u2013vitamin K antagonist oral anticoagulants preceding stroke","volume":"49","author":"Jin","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0049","doi-asserted-by":"crossref","DOI":"10.1177\/10760296221110568","article-title":"Costs and healthcare resource utilization associated with idarucizumab or andexanet Alfa oral anticoagulant reversal in patients hospitalized with life-threatening bleeds","volume":"28","author":"Spyropoulos","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0050","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0051","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1160\/TH12-03-0175","article-title":"The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0\u20131: a nationwide cohort study","volume":"107","author":"Olesen","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2023.07.108_bib0052","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12872-020-01509-x","article-title":"Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort","volume":"20","author":"Said","year":"2020","journal-title":"BMC Cardiovasc Disord"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923006707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923006707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:49:52Z","timestamp":1757573392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914923006707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":52,"alternative-id":["S0002914923006707"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.07.108","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review and Meta-Analysis of Direct Oral Anticoagulants Versus Warfarin in Atrial Fibrillation With Low Stroke Risk","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.07.108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}